Sale!

Oncomine Acute Myeloid Leukemia AML Panel Test

8,260 د.إ

-10%

The Oncomine Acute Myeloid Leukemia (AML) Panel Test is a sophisticated diagnostic tool offered by DNA Labs UAE, specifically designed to provide comprehensive genetic insights into acute myeloid leukemia, a type of cancer that affects the blood and bone marrow. This test utilizes next-generation sequencing technology to analyze multiple genes simultaneously, enabling the identification of genetic mutations and variations that may influence the development, progression, and treatment response of AML.

With a cost of 8260 AED, the Oncomine AML Panel Test is an investment in personalized medicine, offering patients and healthcare providers crucial information that can guide treatment decisions, predict therapeutic responses, and identify potential clinical trial opportunities. By pinpointing specific genetic abnormalities associated with AML, this test facilitates the selection of targeted therapies, potentially improving patient outcomes and reducing the likelihood of adverse reactions to treatment. Conducted at the state-of-the-art facilities of DNA Labs UAE, this test represents a significant step forward in the management and understanding of acute myeloid leukemia.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

ONCOMINE ACUTE MYELOID LEUKAEMIA AML PANEL Test

At DNA Labs UAE, we offer the ONCOMINE ACUTE MYELOID LEUKAEMIA AML PANEL Test, a diagnostic test that uses next-generation sequencing (NGS) technology to detect mutations in genes associated with AML. This test is designed to aid in the diagnosis and management of AML patients by providing information on the genetic mutations present in their cancer cells.

Test Components

The ONCOMINE ACUTE MYELOID LEUKAEMIA AML PANEL Test includes the following components:

  • ABL1
  • ASXL1
  • BCOR
  • BAALC
  • CBL
  • CEBPA
  • DNMT3A
  • EZH2
  • ETV6
  • FLT3
  • GATA2
  • HRAS
  • IDH1
  • IDH2
  • IKZF1
  • JAK2
  • KIT
  • KRAS
  • MYD88
  • MYC
  • MECOM
  • NRAS
  • NPM1
  • NF1
  • PHF6
  • PPRF8
  • PTPN11
  • RUNX1
  • SF3B1
  • SRSF2
  • SMC1A
  • SH2B3
  • STAG2
  • TET2
  • TP53
  • U2AF1
  • WT1
  • ZRSR2

Fusion Genes:

  • ABL1
  • BCL2
  • CCND1
  • CREBBP
  • ETV6
  • FGFR1
  • FGRF2
  • FUS
  • HMGA2
  • JAK2
  • KMT2A
  • MECOM
  • MLL
  • MYH11
  • MMLT3
  • MLLT10
  • NTRK3
  • NUP214
  • PDGFRA
  • PDGFRB
  • RARA
  • RBM15
  • RUNX1
  • TCF3

Test Cost

The cost of the ONCOMINE ACUTE MYELOID LEUKAEMIA AML PANEL Test is AED 8260.0.

Symptoms and Diagnosis

AML is a type of leukemia that affects the bone marrow and blood. Common symptoms of AML include fatigue, shortness of breath, frequent infections, easy bruising or bleeding, and bone pain. Diagnosis of AML typically involves a physical examination, blood tests, and a bone marrow biopsy.

Sample Condition

The sample required for the ONCOMINE ACUTE MYELOID LEUKAEMIA AML PANEL Test is 3 mL (2 mL min.) of whole blood or bone marrow collected in a lavender top (EDTA) tube. The sample should be shipped refrigerated and should not be frozen. A duly filled NGS Test Requisition Form is mandatory.

Report Delivery

The sample for the ONCOMINE ACUTE MYELOID LEUKAEMIA AML PANEL Test should be submitted by the 1st or 16th of every month, and the report will be delivered on the 15th or 30th of the same month.

Method

The ONCOMINE ACUTE MYELOID LEUKAEMIA AML PANEL Test utilizes next-generation sequencing (NGS) technology.

Test Type

The ONCOMINE ACUTE MYELOID LEUKAEMIA AML PANEL Test is specifically designed for the diagnosis of leukemia.

Doctor

The ONCOMINE ACUTE MYELOID LEUKAEMIA AML PANEL Test is recommended to be performed by a hematologist or oncologist.

Test Department

The ONCOMINE ACUTE MYELOID LEUKAEMIA AML PANEL Test is conducted in the Molecular Diagnostics department at DNA Labs UAE.

Pre Test Information

A duly filled NGS Test Requisition Form is mandatory for the ONCOMINE ACUTE MYELOID LEUKAEMIA AML PANEL Test.

Test Details

The ONCOMINE ACUTE MYELOID LEUKAEMIA AML PANEL Test targets 23 genes commonly mutated in AML, including FLT3, NPM1, and IDH1/2. This test provides valuable information on the genetic mutations present in AML patients’ cancer cells, aiding in treatment decisions. The test can be performed on bone marrow or blood samples and has a turnaround time of approximately 7 days.

The ONCOMINE ACUTE MYELOID LEUKAEMIA AML PANEL Test is available through select laboratories and is an important tool for oncologists and hematologists in the diagnosis and treatment of AML patients.

Test Name ONCOMINE ACUTE MYELOID LEUKAEMIA AML PANEL Test
Components ABL1, ASXL1, BCOR, BAALC, CBL, CEBPA, DNMT3A, EZH2, ETV6, FLT3,GATA2, HRAS, IDH1, IDH2, IKZF1, JAK2, KIT, KRAS, MYD88, MYC, MECOM, NRAS, NPM1, NF1, PHF6, PPRF8, PTPN11, RUNX1, SF3B1, SRSF2, SMC1A, SH2B3, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2 FUSION GENES -ABL1, BCL2, CCND1, CREBBP, ETV6, FGFR1, FGRF2, FUS, HMGA2, JAK2, KMT2A,MECOM, MLL, MYH11, MMLT3, MLLT10, NTRK3, NUP214, PDGFRA, PDGFRB, RARA, RBM15, RUNX1, TCF3
Price 8260.0 AED
Sample Condition 3 mL (2 mL min.) whole Blood OR Bone Marrow in 1 Lavender top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Duly filled NGS Test Requisition Formis mandatory.
Report Delivery Sample by 1st / 16th of every month; Report 15th / 30th of Same month
Method NGS
Test type Leukemia
Doctor Hematologist, Oncologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information Duly filled NGS Test Requisition Formis mandatory.
Test Details

The Oncomine Acute Myeloid Leukaemia (AML) Panel is a diagnostic test that uses next-generation sequencing (NGS) technology to detect mutations in genes associated with AML. The panel targets 23 genes commonly mutated in AML, including FLT3, NPM1, and IDH1/2, among others.

The test is designed to aid in the diagnosis and management of AML patients by providing information on the genetic mutations present in their cancer cells. This information can help guide treatment decisions, as certain mutations may be more responsive to specific therapies.

The Oncomine AML Panel can be performed on bone marrow or blood samples from patients with suspected or confirmed AML. The test has a turnaround time of approximately 7 days and is available through select laboratories.

Overall, the Oncomine AML Panel is a valuable tool for oncologists and hematologists in the diagnosis and treatment of AML patients.